FOLATE RECEPTOR EXPRESSION IN PITUITARY ADENOMAS: CELLULAR AND MOLECULAR ANALYSIS

被引:17
作者
Evans, Chheng-Orn [1 ]
Yao, Congjun
LaBorde, David
Oyesiku, Nelson M.
机构
[1] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA
来源
FOLIC ACID AND FOLATES | 2008年 / 79卷
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0083-6729(08)00408-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clinically nonfunctional pituitary adenomas cause hypopituitarism or compression of regional structures. Unlike functional tumors, there is no available medical treatment or specific imaging technique for these tumors. We have recently discovered that both folate receptor (FIR)a mRNA and protein are uniquely overexpressed in nonfunctional pituitary tumors, but not in functional adenomas. We hypothesized that FR alpha may hold significant promise for medical treatment by enabling novel molecular imaging and targeted therapy. Here, we used murine pituitary tumor cell line alpha T3-1 as a model to investigate the biological significance of FRa and its mutant FR67. We demonstrate that overexpression of FIR facilitated tumor cell growth and anchorage-independent growth in soft agar. More colonies were observed in FIR overexpressing cells than in mutant FR67 clones in soft agar. Cell proliferation rate was increased, the percentage of cells in S-phase was increased, and high PCNA staining was detected in cells overexpressing the receptor. In aT3-1 cells transfected with mutant FR67, cell proliferation rate was reduced, the percentage of cells residing in S-phase was slightly decreased, and low PCNA staining was observed. By real-time quantitative PCR, the genes involved in NOTCH3 pathway including NOTCH3, HES-1, and TLE2 were altered; the mRNA expression of FGFR1 was upregulated, and ER beta mRNA was downregulated in FIR overexpressing cells. Our findings suggest that FR alpha plays a role in pituitary tumor formation, and this effect may in part be due to its regulation of the NOTCH3 pathway. (C) 2008 Elsevier Inc.
引用
收藏
页码:235 / +
页数:33
相关论文
共 55 条
  • [1] ANTONY AC, 1992, BLOOD, V79, P2807
  • [2] CLINICALLY NONFUNCTIONING HUMAN PITUITARY-ADENOMAS
    ASA, SL
    KOVACS, K
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1992, 19 (02) : 228 - 235
  • [3] HUMAN PITUITARY NULL-CELL ADENOMAS AND ONCOCYTOMAS INVITRO - EFFECTS OF ADENOHYPOPHYSIOTROPIC HORMONES AND GONADAL-STEROIDS ON HORMONE-SECRETION AND TUMOR-CELL MORPHOLOGY
    ASA, SL
    CHENG, Z
    RAMYAR, L
    SINGER, W
    KOVACS, K
    SMYTH, HS
    MULLER, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (05) : 1128 - 1134
  • [4] The cytogenesis and pathogenesis of pituitary adenomas
    Asa, SL
    Ezzat, S
    [J]. ENDOCRINE REVIEWS, 1998, 19 (06) : 798 - 827
  • [5] Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression
    Bagnoli, M
    Tomassetti, A
    Figini, M
    Flati, S
    Dolo, V
    Canevari, S
    Miotti, S
    [J]. ONCOGENE, 2000, 19 (41) : 4754 - 4763
  • [6] Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis
    Bellavia, D
    Campese, AF
    Checquolo, S
    Balestri, A
    Biondi, A
    Cazzaniga, G
    Lendahl, U
    Fehling, HJ
    Hayday, AC
    Frati, L
    von Boehmer, H
    Gulino, A
    Screpanti, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) : 3788 - 3793
  • [7] HORMONE PRODUCTION IN CLINICALLY NONFUNCTIONING PITUITARY-ADENOMAS
    BLACK, PM
    HSU, DW
    KLIBANSKI, A
    KLIMAN, B
    JAMESON, JL
    RIDGWAY, EC
    HEDLEYWHYTE, ET
    ZERVAS, NT
    [J]. JOURNAL OF NEUROSURGERY, 1987, 66 (02) : 244 - 250
  • [8] BOTTERO F, 1993, CANCER RES, V53, P5791
  • [9] Bradshaw C, 2007, HISTOL HISTOPATHOL, V22, P219, DOI 10.14670/HH-22.219
  • [10] EXPRESSION OF EPIDERMAL GROWTH-FACTOR (EGF), ITS RECEPTOR, AND RELATED ONCOPROTEIN (ERBB-2) IN HUMAN PITUITARY-TUMORS AND RESPONSE TO EGF IN-VITRO
    CHAIDARUN, SS
    EGGO, MC
    SHEPPARD, MC
    STEWART, PM
    [J]. ENDOCRINOLOGY, 1994, 135 (05) : 2012 - 2021